[{"indications": "Indications\u00a0pulmonary arterial hypertension ", "name": "AMBRISENTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.1 Vasodilator antihypertensive drugs", "AMBRISENTAN"], "cautions": "Cautions\u00a0not to be initiated in significant anaemia; monitor haemoglobin concentration or haematocrit after\r\n1 month and 3 months of starting treatment, and periodically thereafter (reduce dose or discontinue treatment if significant\r\ndecrease in haemoglobin concentration or haematocrit observed); monitor liver function before treatment, and monthly\r\nthereafter\u2014discontinue if liver enzymes raised significantly\r\nor if symptoms of liver impairment develop", "side-effects": "Side-effects\u00a0abdominal pain, constipation; palpitation, flushing,\r\nperipheral oedema; upper respiratory-tract disorders; headache; anaemia; less commonly hypersensitivity reactions (including angioedema\r\nand rash)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201151.htm", "doses": ["adult over 18 years, 5\u00a0mg\r\nonce daily, increased if necessary to 10\u00a0mg once daily"], "pregnancy": "Pregnancy\u00a0avoid (teratogenic in animal studies);\r\nexclude pregnancy before treatment and ensure effective contraception\r\nduring treatment; monthly pregnancy tests advised"}]